The Sonic Healthcare Limited (ASX: SHL) share price has fallen almost 4% to $23.30 in early trade following the release of the healthcare company’s half-year results. Here are key takeaways from the release: Half-year revenue was 8% higher on the prior corresponding period to $2,673 million. Earnings before interest, tax, depreciation, and amortisation (EBITDA) was 9% higher at $445 million. First-half net profit after tax was up 16% to $229 million or 6% to $209 million excluding the US net tax benefit. Earnings per share of 54.1 cents for the half (49.4 cents excluding US net tax benefit). Outlook: On…
You can continue reading this story now by entering your email below
The Sonic Healthcare Limited (ASX: SHL) share price has fallen almost 4% to $23.30 in early trade following the release of the healthcare company’s half-year results.
Here are key takeaways from the release:
- Half-year revenue was 8% higher on the prior corresponding period to $2,673 million.
- Earnings before interest, tax, depreciation, and amortisation (EBITDA) was 9% higher at $445 million.
- First-half net profit after tax was up 16% to $229 million or 6% to $209 million excluding the US net tax benefit.
- Earnings per share of 54.1 cents for the half (49.4 cents excluding US net tax benefit).
- Outlook: On track to achieve full-year guidance of 6% to 8% EBITDA growth.
Overall I thought that Sonic Healthcare’s performance was solid during the first-half, though perhaps not strong enough to justify the multiples its shares were previously trading on.
During the period the company reported a 5% increase in like-for-like revenue (in constant currency) across the entirety of its business operations when normalised for working days. Sonic Healthcare was operating for fewer working days compared to the prior corresponding period due to two hurricanes impacting its U.S. business.
A highlight of the half was the performance of its Australian laboratory business. The business continues to report growing earnings and margins, having rebounded from abnormal cost growth due to industry issues for several years.
Pleasingly, there appears to be no danger of these issues coming back any time soon. Management advised that these cost control measures are still in place and it remains confident that its largest segment will continue its growth unabated.
Elsewhere, its German business reported a 20% increase in revenue thanks partly to the synergistic acquisitions of Laboratory Bremen and the Staber laboratory group. Integration of these highly respected laboratories is proceeding to plan, including the first physical laboratory merger, in Hamburg, being successfully completed in the first-half.
Looking ahead, for the full-year management has reaffirmed its guidance of 6% to 8% growth in underlying EBITDA year-on-year despite posting a 9% increase during the first-half.
Should you invest?
At present Sonic Healthcare’s shares are changing hands at 21x trailing earnings including U.S. tax benefits. Given its guidance for 6% to 8% growth, I think this is a touch on the expensive side.
As a result, I would suggest investors wait for a sizeable pull-back in order to gain a better entry point. In the meantime, I prefer healthcare peers Ramsay Health Care Limited (ASX: RHC) and Nanosonics Ltd. (ASX: NAN).
Alternatively, these stellar growth shares could be even better options for investors.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.